Skip to Main content Skip to Navigation
Journal articles

Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.

Abstract : BACKGROUND: Recent studies have demonstrated that blockade of the angiotensin II type 1 receptor with losartan decreases aortic damage in an animal model of Marfan syndrome (a KI mouse model with a pathogenic mutation in the gene coding for fibrillin-1). AIMS: To demonstrate a beneficial effect of losartan on aortic dilatation when added to optimal therapy in patients with Marfan syndrome. METHODS: This is a multicentre, randomized, placebo-controlled, double-blind, clinical trial with a 2-year inclusion period and a 3-year follow-up period. Aortic root diameter will be measured using two-dimensional echocardiography. Secondary endpoints will include incidence of aortic dissection, aortic root surgery, death, quality of life, tolerance and compliance with treatments. We aim to enroll a total of 300 patients aged > or =10 years who fulfil the Ghent criteria for Marfan syndrome. Analyses will be based on intention to treat. CONCLUSION: The results of this clinical trial could lead to profound modification of the management of aortic risk and complications in patients with Marfan syndrome and possibly in patients with thoracic aortic aneurysms of other aetiologies.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00511671
Contributor : Hervé de Villemeur <>
Submitted on : Wednesday, August 25, 2010 - 4:12:34 PM
Last modification on : Wednesday, August 19, 2020 - 12:08:07 PM

Identifiers

Citation

Delphine Detaint, Philippe Aegerter, Florence Tubach, Isabelle Hoffman, Henri Plauchu, et al.. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.. Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2010, 103 (5), pp.317-25. ⟨10.1016/j.acvd.2010.04.008⟩. ⟨inserm-00511671⟩

Share

Metrics

Record views

676